ABL DiagnosticsXPAR:ABLD +0.80%50 PS Ratio is 5.83 as of Jul. 12, 2026, which is 63% below its 10-year median of 15.60. GuruFocus rates XPAR:ABLD with a GF Score™ of 50/100 and a GF Value™ of €7.77 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 659 Healthcare Providers & Services companies, ABL Diagnostics ranks worse than 83.16% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ABL Diagnostics's share price is €2.52.
ABL Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.43. Hence, ABL Diagnostics's PS Ratio for today is 5.83.
Good Sign:
ABL Diagnostics stock PS Ratio (=5.82) is close to 10-year low of 5.54.
The historical rank and industry rank for ABL Diagnostics's PS Ratio or its related term are showing as below:
XPAR:ABLD'
s PS Ratio Range Over the Past 10 Years
Min: 5.54 Med: 15.6 Max: 94.04
Current: 5.83
During the past 13 years, ABL Diagnostics's highest PS Ratio was 94.04. The lowest was 5.54. And the median was 15.60.
XPAR:ABLD's PS Ratio is ranked worse than 83.16% of 659
companies
in the Healthcare Providers & Services industry
Industry Median: 1.48
vs XPAR:ABLD: 5.83
ABL Diagnostics revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of ABL Diagnostics was 30.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -7.30% per year.
During the past 13 years, ABL Diagnostics's highest 3-Year average Revenue per Share Growth Rate was 279.80% per year. The lowest was -58.30% per year. And the median was 2.00% per year.
Back to Basics: PS Ratio
ABL Diagnostics (XPAR:ABLD) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
ABL Diagnostics PS Ratio Related Terms
ABL Diagnostics PS Ratio Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, ABL Diagnostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's PS Ratio distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
ABL Diagnostics's Share Price of today is €2.52.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.43.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ABL Diagnostics (XPAR:ABLD) has a PS Ratio of 5.83 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ABL Diagnostics and its competitors. This is 63% below median its historical median of 15.60. Over the past decade, ABL Diagnostics' PS Ratio has ranged from 5.54 to 94.04. According to the industry distribution chart, ABL Diagnostics ranks #548 out of 659 companies in the Healthcare Providers & Services industry, placing it in the top 83.2%.
Is ABL Diagnostics' PS Ratio too high?
ABL Diagnostics' current PS Ratio of 5.83 is 63% below median its 10-year median of 15.60. Over the past 10 years, this metric has ranged from a low of 5.54 to a high of 94.04. The Healthcare Providers & Services industry median PS Ratio is 1.48. ABL Diagnostics' value of 5.83 is 293.9% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #548 out of 659 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' PS Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #548 out of 659 companies for PS Ratio. This places ABL Diagnostics in the lower half of its industry. The industry median PS Ratio is 1.48. ABL Diagnostics' value of 5.83 is 293.9% above this benchmark. Historically, ABL Diagnostics' own PS Ratio has ranged from 5.54 to 94.04 over the past decade. While the company's 10-year median is 15.60 vs. the industry median of 1.48, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.48, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current PS Ratio of 5.83 is 293.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current PS Ratio is 5.83, which is 63% below median its own 10-year median of 15.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.77, compared to a current price of €2.52 — trading 67.6% below its estimated fair value. The current PS Ratio is 5.83, which is 63% below median its 10-year median of 15.60 and 293.9% above the Healthcare Providers & Services industry median of 1.48. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current PS Ratio is 5.83 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.52 is trading 67.6% below its estimated GF Value™ of €7.77.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
PS Ratio: 5.83 (63% below median its 10-year median of 15.60)
GF Value™: €7.77 vs. price of €2.52 (67.6% below fair value)
Industry Position: 293.9% above the Healthcare Providers & Services median (#548 of 659)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score
Get the complete analysis for XPAR:ABLD
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
